In vitro and clinical evaluation of SIG1273: a cosmetic functional ingredient with a broad spectrum of anti-aging and antioxidant activities.

TitleIn vitro and clinical evaluation of SIG1273: a cosmetic functional ingredient with a broad spectrum of anti-aging and antioxidant activities.
Publication TypeJournal Article
Year of Publication2016
AuthorsFernández, JR, Rouzard, K, Voronkov, M, Huber, KL, Webb, C, Stock, JB, Stock, M, Gordon, JS, Pérez, E
JournalJ Cosmet Dermatol
Volume15
Issue2
Pagination150-7
Date Published2016 Jun
ISSN1473-2165
KeywordsAdministration, Cutaneous, Adult, Cell Movement, Cells, Cultured, Cysteine, Esthetics, Fibroblasts, Follow-Up Studies, Humans, In Vitro Techniques, Middle Aged, Oxidation-Reduction, Patient Satisfaction, Prospective Studies, Skin Aging, Treatment Outcome
Abstract

<p><b>BACKGROUND: </b>Isoprenylcysteine (IPC) small molecules were identified as a new class of anti-inflammatory compounds over 20 years ago. Since then, they have been developed as novel cosmetic functional ingredients (CFI) and topical drug candidates. SIG1273 is a second generation CFI that has previously been shown to provide a broad spectrum of benefits for the skin through its anti-inflammatory and antimicrobial properties.</p><p><b>OBJECTIVE: </b>To determine whether SIG1273 possesses anti-aging properties in vitro and evaluate the tolerability and activity of SIG1273 when applied topically to human subjects.</p><p><b>METHODS: </b>To model photoaging in vitro, human dermal fibroblasts (HDFs) were exposed in culture to UVA to induce collagenase (MMP-1) production. An in vitro wound-healing model was based on the activation of HDF migration into cell-free tissue culture surface. Hydrogen peroxide-induced oxidative stress was performed using HDFs to measure intracellular ROS activity. Radical scavenging capacity was determined using a colorimetric antioxidant assay kit (ABTS method). Lastly, a 4-week, 29-subject study was performed in which SIG1273 was applied topically as a cream to assess its tolerance and activity in reducing the appearance of aging.</p><p><b>RESULTS: </b>In vitro studies demonstrate SIG1273 inhibits UVA-induced MMP-1 production, hydrogen peroxide-induced oxidative stress and promotes wound healing. Moreover, SIG1273 was shown to be a radical scavenging antioxidant. Clinical assessment of SIG1273 cream (0.25%) showed it was well tolerated with significant improvement in the appearance of fine lines, coarse wrinkles, radiance/luminosity, pore size, texture/smoothness, hydration and increased firmness.</p><p><b>CONCLUSIONS: </b>SIG1273 represents a novel CFI with antioxidant, anti-aging, and anti-inflammatory properties that when applied topically is well tolerated and provides benefits to individuals with aging skin.</p>

DOI10.1111/jocd.12206
Alternate JournalJ Cosmet Dermatol
PubMed ID26754448